4
Changes in Ownership
Acrivon Therapeutics, Inc. Filed Acc 0001209191-22-057395
President and CEO acquired 1,524,947 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Blume-Jensen Peter · President and CEO
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-11-14 | Grant or award : show line 1 in the form | +934,731 | 1,806,588 | D |
| 2022-11-14 | Grant or award : show line 2 in the form | +503,419 | 2,310,007 | D |
| 2022-11-14 | Grant or award : show line 3 in the form | +60,090 | 2,370,097 | D |
| 2022-11-14 | Grant or award : show line 4 in the form | +26,707 | 320,705 | I |
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-11-14 | Grant or award : show line 5 in the form Stock Option (Right to Buy) | +180,269 | 180,269 | D |
| 2022-11-14 | Grant or award : show line 6 in the form Stock Option (Right to Buy) | +80,120 | 80,120 | I |
Loading xslF345X03/doc4.xml…